<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478032</url>
  </required_header>
  <id_info>
    <org_study_id>20194Y0037</org_study_id>
    <nct_id>NCT04478032</nct_id>
  </id_info>
  <brief_title>Deep Transcranial Magnetic Stimulation for the Treatment of Treatment Resistance Schizophrenia</brief_title>
  <official_title>Deep Transcranial Magnetic Stimulation for the Treatment of Treatment Resistance Schizophrenia: a Double-Blind, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the hypothesis that low-frequency deep transcranial magnetic stimulation(dTMS) on
      anterior cingulate cortex （ACC） could down-regulate the glutamate level of ACC and regulate
      the acc-related functional network in patients with treatment resistance schizophrenia,this
      research plan to utilise multimodal functional magnetic imaging method(including structural
      MRI,resting-state functional magnetic resonance imaging and 1H-MRS) to investigate
      therapeutic efficacy of low-frequency deep transcranial magnetic stimulation on SZ patients
      symptoms,as well as to elucidate the correlation between treatment effects and glutamate
      level of ACC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes 20 treatment resistance schizophrenia patients and 20 healthy
      controls.This study will investigate 1)abnormalities of the glutamate level of ACC in
      patients with schizophrenia compared to healthy controls by using 1H-MRS technique.
      2)potential modulation effects of deep transcranial magnetic stimulation(dTMS) on anterior
      cingulate cortex function of patients with schizophrenia. 3)the therapeutic efficacy of dTMS
      on cognitive impairments and other psychotic symptoms of patients with schizophrenia by
      adopting cognitive function and psychotic symptoms evaluation,as well as to explore the
      optimal dTMS treatment pattern on cognitive function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this research,we combine a cross-sectional case control study and a randomized controlled study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale(PANSS)</measure>
    <time_frame>baseline,24 hours after the dTMS treatment,30 days</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale(PANSS) after dtms treat 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in MATRICS Consensus Cognitive Battery</measure>
    <time_frame>baseline,24 hours after the rTMS treatment,30 days</time_frame>
    <description>MATRICS Consensus Cognitive Battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of ACC neurogenesis</measure>
    <time_frame>baseline,24 hours after the dTMS treatment</time_frame>
    <description>Quantify neural stem cells in hippocampal by using H1-MRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glutamate level</measure>
    <time_frame>baseline,24 hours after the dTMS treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Deep Transcranial Magnetic Stimulation for the Treatment of Treatment Resistance Schizophrenia</condition>
  <arm_group>
    <arm_group_label>sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>20 patients will be randomly allocated into this group,they will receive sham stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real stimulation dTMS targeting the ACC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients will be randomly allocated into this group,they will receive real stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>deep transcranial magnetic stimulation with H7 coil</intervention_name>
    <description>low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.</description>
    <arm_group_label>real stimulation dTMS targeting the ACC</arm_group_label>
    <arm_group_label>sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) patients with schizophrenia who meet the dsm-5 diagnostic criteria;(2) aged from
             18 to 60;(3) after 4 weeks of treatment with a sufficient dose of an antipsychotic
             (equivalent dose of 400 ~ 600 mg/ day chlorpromazine (CPZ)), no clinical improvement
             was achieved (at least two items in PANSS scale P1,P2,P3,N1,N4,N6,G5 and G9 ≥4 points,
             or cgi-s ≥4 points).(3) right-handedness, normal hearing, visual acuity or corrected
             visual acuity;(4) written informed consent of the patient and his/her family.

        Exclusion Criteria:

          -  (1) patients who are currently taking clozapine or who have failed to respond to a
             full course of treatment with clozapine;(2) Current or past neurological
             illness,severe physical illness,substance abuse or addiction,alcohol dependence,mental
             retardation,pregnancy or lactation,extreme agitation, stupor, negative suicide,or
             those who can not cooperate.A history of MECT within 6 months,or those with
             contraindications to MRI,rTMS.Medically unstable for at least 1 month (PANSS score
             fluctuation＞10%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dengtang Liu, M.D.</last_name>
    <phone>8618017311138</phone>
    <email>erliu110@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dengtang LIU</last_name>
      <phone>8618017311138</phone>
      <email>erliu110@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Resistance Schizophrenia</keyword>
  <keyword>Deep Transcranial Magnetic Stimulation</keyword>
  <keyword>anterior cingulate cortex</keyword>
  <keyword>glutamate</keyword>
  <keyword>H7 coil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

